Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Part of paid clinical trials in Newport Beach, California.

Sponsor
Hoag Memorial Hospital Presbyterian
Study ID
NCT00003663
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • dexamethasone — DRUG

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining the monoclonal antibody rituximab with dexamethasone may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and dexamethasone in treating patients with recurrent or refractory indolent non-Hodgkin's lymphoma.

Key Dates

Start date
Jun 30, 1998
Status verified
Aug 2015
Primary completion
Jan 31, 2000
Completion
Jan 31, 2000

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Locations (3)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92658-
Cancer Care Center for Southern IndianaBloomingtonIndiana47403-
St. Joseph Regional Cancer CenterBryanTexas77802-

Find similar trials in Newport Beach, CA

By research site
Hoag Memorial Hospital Presbyterian· Newport Beach, CACancer Care Center for Southern Indiana· Bloomington, INSt. Joseph Regional Cancer Center· Bryan, TX

Related Studies